 Home > Medical News > Latest Medical News > Top20 announced! Yangtze River and China Resources Sanjiu lead the stomach medicine market

Top20 announced! Yangtze River and China Resources Sanjiu lead the stomach medicine market

 Last Update: 2022-10-19
 Source: Internet
 Author: User

Tags

natural products company

non corrosive metals

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

In the second half of this year, the good news of Class 1 new drugs of gastric medicine and traditional Chinese medicine continued: Tong Drop granules were declared for clinical trial in August, and Ollanti Gastro Kang tablets were declared for marketing in September; The adjustment of the 2022 version of the medical insurance catalogue has entered the end, and the expert review work has been completed, and whether the Class 1 new drug Qirui Gastric Comfort Capsule can be "insured" has attracted much attention.
.
.

In recent years, proprietary Chinese medicine for the treatment of stomach diseases has gradually been favored by patients, market demand has surged, and a number of policies are conducive to the research and development of new drugs, and the market trend has been continuously strengthened
.
China's public medical institution terminals and China's urban physical pharmacy terminals Chinese proprietary medicine gastric medicine market may usher in a big reshuffle, who is the big winner?

01.
Medical insurance helps take off, and Class 1 new drugs are surging

At the end of 2021, Jianmin Pharmaceutical Group's Qirui Gastric Comfort Capsules were approved for marketing for mild to moderate chronic non-atrophic gastritis with erosion, moist heat and obstruction of gastric pain
.
This new drug is the first Class 1 new drug approved in the gastric medicine market of proprietary Chinese medicine in the past ten years, which brings positive significance
to the research and development of innovative Chinese medicine drugs in China.

In April 2022, CDE publicly solicited opinions on the Guidelines for the Evaluation of the Clinical Efficacy of New Chinese Medicines for Chronic Gastritis and the Guidelines for the Evaluation of Clinical Efficacy of New Chinese Medicines for Gastroesophageal Regurgitation Disease.

The declaration of Class 1 new drugs of gastric medicine since 2022

In August this year, Jianmin Pharmaceutical Group submitted a clinical application for a class 1.
1 new drug with Tong Drop Granules, which is a hospital-based preparation transformation of Xiyuan Hospital of the Chinese Academy of Chinese Medical Sciences for the treatment of non-erosive gastroesophageal reflux disease
.
This new drug is the second innovative drug
of Jianmin Pharmaceutical Group in the field of proprietary Chinese medicine gastric medicine.

In September this year, Jiangxi Qingfeng Pharmaceutical's Class 1.
2 new drug Olantigastric Kang tablets was declared for marketing, which is an oral preparation made from the total flavonoside extract extracted from the local medicinal material Citrus aurantium in Jiangxi Province, which is used to treat gastrointestinal dyskinesia functional dyspepsia
.
Jiangxi Qingfeng Pharmaceutical has only won the production approval of monkey mushroom drink oral liquid in the Chinese proprietary medicine gastric medicine market, and Ollantic Gastro Kang tablets are expected to become its first Class 1 new drug
in this field.

At present, the research and development of new proprietary Chinese medicine gastric drugs has gradually entered a bumper harvest period, and in order to accelerate the entry of innovative drugs into the market, the dynamic adjustment of medical insurance has become the strongest help
.

In 2020, the medical insurance catalogue was adjusted, the exclusive product Ganhai Gastrokang capsules and stomach clearing pain-relieving pellets were successfully negotiated, from the provincial catalogue to the national medical insurance catalogue, the number of proprietary Chinese medicine gastric medicines in the 2020 and 2021 editions of the national medical insurance catalogue was the highest in recent years, all of which were 109 products (by product name).

Shaanxi Dongke Pharmaceutical (a subsidiary of Jichuan Pharmaceutical) Ganhai Gastrokang capsules have entered the provincial supplementary catalogue of Shaanxi, Inner Mongolia, Jiangxi, Jiangsu, Henan and Hebei, and are now Class B varieties
of the 2021 edition of the medical insurance negotiation catalogue.
According to data from Intranet, at the terminals of urban public hospitals, county-level public hospitals, urban community centers and township health centers (referred to as China's public medical institutions), the sales growth rate of the product was 4.
6% in 2020, 14.
8% in 2021, and more than 148%
in the first half of 2022.

The stomach clearing and analgesic pills of Jilin Huakang Pharmaceutical (a subsidiary of Changchun High-tech) have entered the provincial supplementary catalogues of Yunnan, Shandong, Jilin, Hainan, Guangxi and Anhui, and are now Class B varieties
of the 2021 edition of the medical insurance negotiation catalogue.
At the end of China's public medical institutions, the sales growth rate of the product was -12.
4% in 2020, close to 160% in 2021, and more than 294%
in the first half of 2022.

Sales of the two new exclusive products of medical insurance in recent years (10,000 yuan)

The unification of the national medical insurance catalogue is the general policy, and the "promotion" of supplementary varieties to the national catalogue can not only benefit more patients, but also promote the sales of products, and it is also a fast channel
for innovative drugs.

Jianmin Pharmaceutical Group recently said in response to investor inquiries that Qirui gastric comfort capsules have been sold in some provinces and regions, but the sales volume is small
.
In 2022, the national medical insurance catalogue adjustment through the formal review of the drug list was announced on September 17, Qirui gastric comfort capsules on the list, the new drug formula comes from the hospital preparation of Guanganmen Hospital of the Chinese Academy of Chinese Medical Sciences, has a good clinical application foundation, if successfully entered the medical insurance, or will usher in a high-speed volume, the potential can be expected
.

02.
Yangtze River has a solid leading position

Lifang Pharmaceutical and Jichuan Pharmaceutical exploded

According to the latest data, in the first half of 2022, the market size of proprietary Chinese medicine gastric medicines (gastritis, ulcers) in China's public medical institutions continued to maintain positive growth, with sales exceeding 3.
7 billion yuan
.
The TOP3 enterprises continue to be occupied by Yangtze Jiangsu Pharmaceutical, Sichuan Good Doctor Panxi Pharmaceutical and Hunan Kelun Pharmaceutical, which together control 40% of the market
.

Yangtze River Jiangsu Pharmaceutical has been firmly in the top 1 enterprise of proprietary Chinese medicine gastric medicine from 2018 to the first half of 2022, with its market share increasing from 12.
18% to 15.
99%, and the market share of TOP2 enterprises in the first half of 2022 is 13.
14%, and Yangtze Jiangsu Pharmaceutical has obvious
leading advantages.

In the first half of 2022, China's public medical institutions will end the top 20 brands of proprietary Chinese medicine gastric medicines

Note: Sales below 100 million yuan are replaced by *

In the first half of 2022, 13 of the top 20 brands are exclusive, Yangtze Jiangsu Pharmaceutical accounts for two, and the ranking of gastric su granules and cubebell stomach pain granules remains in the TOP3 and TOP4
.

Cubebell stomach pain granules are based on the classic digestive formula "Golden Bell Zisan" and "Zuo Jinmaru" with flavor improvement, and are used to treat chronic
gastritis, functional dyspepsia, peptic ulcer and gastroesophageal reflux disease.

Since its launch, the product has maintained a super high-speed growth trend in the terminals of public medical institutions in China, only 1 million yuan in 2016, exceeded 100 million yuan in 2019, rose to 400 million yuan in 2021, and won 270 million yuan in sales in the first half of 2022, which is close to the level of
the whole year of 2020.

From the perspective of channels, the proportion of urban public hospitals will remain at about 60% in the first half of 2022, while county-level public hospitals will rise to 16%, and urban community centers will reach more than 12%, and the effect of product channel sinking is very significant
.

Hefei Lifang Pharmaceutical's exclusive product Yiqi and Gastric Capsules rose four places in the first half of 2022, which is used to treat chronic non-atrophic gastritis spleen and stomach weakness and gastric heat stasis obstruction
.

Since entering the 2017 edition of the medical insurance catalog, the sales of the product have grown rapidly, exceeding 100 million yuan in 2021 and more than 50%
in the first half of 2022.
From the perspective of channels, in the first half of 2022, the proportion of the main battlefield of county-level public hospitals rose slightly to 52%, the proportion of urban public hospitals remained at 22%, and the proportion of urban community centers and township health centers was above
10%.

Ganhai Gastric Kang capsules, an exclusive product of a subsidiary of Jichuan Pharmaceutical, are new brands on the list in the first half of 2022, which are used to treat gastric and duodenal ulcers, chronic gastritis, reflux esophagitis and other diseases
caused by spleen deficiency and stagnation.
The product is one of the successful cases of the "promotion" of the provincial directory to the national directory, and the sales in the first half of 2022 have exceeded the level
of the whole year of 2020.

From the perspective of channels, in the first half of 2022, urban public hospitals and county-level public hospitals are the main battlefield, accounting for 51% and 42% respectively, and the proportion of urban community centers and township health centers is gradually expanding
.

03.
China Resources 39 leads the way

Non-exclusive products are on the offensive

According to the latest forecast data, the market size of proprietary Chinese medicine (gastritis, ulcer) in China's urban physical pharmacies will maintain positive growth in 2022, with sales exceeding 2.
7 billion yuan
.
China Resources Sanjiu Pharmaceutical has ranked first with a market share of more than 10% in recent years, Sichuan Good Doctor Panxi Pharmaceutical's market share is expected to rise to 10.
35% in 2022, Yangtze River Jiangsu Pharmaceutical continues to rank third, the total share of TOP3 enterprises is less than 30%, and the market concentration is not too high
.

2022E China urban physical pharmacy terminal proprietary medicine stomach medicine TOP20 brand

Note: Sales below 1 million yuan are replaced by *

There are 11 TOP20 brands that are exclusive, and only China Resources Sanjiu Pharmaceutical's sales of Sanjiu gastric Tai granules exceed 300 million yuan
.
The product is used to treat gastric pain caused by moist heat and blood stasis, and superficial gastritis, and has been firmly in the top 1 brand throne from 2016 to 2021, and sales are expected to increase by 9.
05% in 2022, and the market leading position is difficult to shake
.

Hefei China Resources Shenlu Pharmaceutical's stomach comfort granules are expected to have no major changes in their ranking in 2022, but their potential should not be
underestimated.
The product is used to treat chronic gastritis, and the sales growth rate from 2016 to 2021 will remain double-digit, and the growth rate is expected to reach 10.
08% in 2022, and the sales will rise to more than
70 million yuan.

In terms of non-exclusives, Remegen Pharmaceutical's (Zibo) liver and stomach pills entered the TOP20 brands for the first time in 2021, and are expected to rise 5 places in the ranking in 2022, with a growth rate of more than 80%.

The product is used to treat liver and stomach discord, swelling of the two flanks, stomach pain, loss of appetite, etc.
, and the number of companies that have obtained approvals is more than 40, and Remegen Pharmaceutical (Zibo) is expected to seize more than 60% of the market share
in 2022.

Zhongjing Wanxi Pharmaceutical's fragrant sand Liujun pills have become a new brand on the list in 2022, the product is used to treat spleen deficiency and stagnation, indigestion, belching, less belching, abdominal distension, etc.
, the number of companies that have obtained approvals is more than 70, and the market share of Zhongjing Wanxi Pharmaceutical remains above
80%.

In addition, Henan Lingrui Pharmaceutical's abdominal relief patch is the only patch on the list, which is used to treat stomach pain
.
At present, there are 3 enterprises that have obtained approval for this product, and the market share of Henan Lingrui Pharmaceutical is as high as 90%.

04.
Conclusion

With the acceleration of the pace of life, the incidence of gastritis, ulcers and other gastric diseases is constantly increasing, and traditional Chinese medicine has a dual-layer effect of treatment and conditioning for gastropathy, which is more and more favored by patients, and has also attracted the attention of domestic pharmaceutical companies
.

At present, the scale of the market for proprietary Chinese medicine gastric medicine is rising, showing strong potential, major brands are making efforts to grab food, innovative drugs are also expected to ride the wind and waves through medical insurance, the market is unpredictable, only the strong can win
.

Source: Intranet database, company announcements, etc

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.